|
新闻
BioForm Announces Pricing of Initial Public Offering
SAN MATEO, CA - Nov 07, 2007 - ABioForm Medical, Inc. (Nasdaq: BFRM) today
announced the initial public offering of 10,000,000 shares of common
stock at a price of $8.00 per share. BioForm has granted the
underwriters a 30-day option to purchase up to an additional 1,500,000
shares at the initial public offering price to cover over-allotments, if
any. The common stock will trade on the Nasdaq Global Market under the
symbol "BFRM."
J.P. Morgan Securities Inc. and Piper Jaffray & Co. are serving as joint
book-running managers for the offering, with CIBC World Markets Corp. and
Jefferies & Company, Inc. serving as co-managers.
A registration statement relating to these securities has been filed with, and
declared effective by, the U.S. Securities and Exchange Commission. This press
release shall not constitute an offer to sell or the solicitation of an offer to
buy nor shall there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.
A copy of the final prospectus for the offering may be obtained from the
prospectus department of either J.P. Morgan Securities Inc., 4 Chase Metrotech
Center, CS Level, Brooklyn, NY 11245, or by calling (718) 242-8002; or Piper
Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling
(877) 371-5212.
About BioForm Medical, Inc.
BioForm Medical, Inc. is a medical aesthetics company headquartered in
San Mateo, California. BioForm is dedicated to bringing doctors and
their patients safe and effective products for use in the dermatology,
plastic surgery and ENT markets. BioForm's products include Radiesse(R),
a long-lasting filler for use in facial aesthetics and vocal fold
insufficiency, and Coaptite(R) for treating female stress urinary
incontinence which is marketed through a partnership with Boston
Scientific Corporation. BioForm has licensed U.S. marketing rights to
Aethoxysklerol(R), the worldwide leading sclerotherapy agent, which is
currently being evaluated in a Phase III clinical trial. BioForm has
also licensed BioGlue, a new surgical adhesive product for plastic
surgery applications, which is being developed in a partnership with
CryoLife, Inc.
« 回 新闻
|
